At the BioProcess International in Boston 27-30 Sept we had the pleasure to talk to Andrew Lees, founder of Fina Biosolutions and to hear a little about their role in the field of vaccine development.
Fina Biosolutions is located in the heart of Maryland’s biotechnology corridor and was founded by Dr. Andrew Lees in 2006. FinaBio was helps emerging market vaccine manufacturers learn to make affordable protein polysaccharide conjugates for vaccines and is now a premier provider of conjugate vaccine laboratory and consulting services for the Biotech and Vaccine industry throughout the world.
Hear some more about
- conjugate vaccines and mRNA vaccines in general
- what Dr. Lees thinks will happen in the next 5 years in the industry and
- his eureka moment that started it all
About Andrew Lees
Dr. Andrew Lees holds over 20 patents and is the author or co-author of more than 60 peer-reviewed papers. He holds a B.S. in Chemistry from Harvey Mudd College and a Ph.D. in Biophysics from The Johns Hopkins University. GlaxoSmithKline, the Serum Institute of India, the Chengdu Institute of Biological Products, and others all use conjugation chemistry (CDAP) developed by Dr. Lees in their S. pneumonia and meningococcal conjugate vaccines. Dr. Lees also teaches protein chromatography through the post-graduate level and is a frequent speaker on conjugation chemistry and biotech entrepreneurship.
